Avax Technologies Return on Equity

Avax Technologies (AVXT) currently reports a ROE of 353.75%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Avax Technologies's ROE history and peer comparisons.

Avax Technologies's ROE of 353.75% is higher than the Healthcare sector average of 11.15%. That is roughly 3071.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Avax Technologies's current 353.75% should be judged against Healthcare norms (sector average: 11.15%) and against AVXT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 353.75%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Avax Technologies, and consider following AVXT for alerts when major investors trade the stock.

Avax Technologies is classified in the Healthcare sector. On ROE, it currently shows 353.75% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AVXT with unrelated industries.